How can we facilitate research on the risks and potential benefits of novel psychoactive substances?
EClinicalMedicine June 19, 2026 DOI: 10.1016/j.eclinm.2026.104030 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|
Abstract
How can we facilitate research on the risks and potential benefits of novel psychoactive substances?
Citations in the library
Cites 18
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine June 1, 2021
- Illegal Drugs Laws: Clearing a 50-Year-Old Obstacle to Research PLoS Biology January 27, 2015
- Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics Frontiers in Psychiatry February 11, 2020
- Neurocognition and subjective experience following acute doses of the synthetic cannabinoid JWH‐018: a phase 1, placebo‐controlled, pilot study British Journal of Pharmacology November 22, 2017
- Assessment of the Acute Effects of 2C‐B vs. Psilocybin on Subjective Experience, Mood, and Cognition Clinical Pharmacology & Therapeutics May 30, 2023
and 13 more in the library